Literature DB >> 30658811

A potential carrier for anti-tumor targeted delivery-hyaluronic acid nanoparticles.

Jia Cai1, Jingru Fu2, Ruirui Li3, Fang Zhang4, Guixia Ling5, Peng Zhang6.   

Abstract

In recent years, biomacromolecules have been widely used in anti-tumor delivery systems due to the biocompatibility and biodegradability. However, their applications are limited due to the lack of specific targeting. Hyaluronic acid (HA) is a natural polysaccharide and presents in extracellular matrix and synovial fluid which can specifically recognize receptors over-expressed by tumor cells. In addition, they can self-assemble into nanoparticles. HA nanoparticles provide new hierarchical targeting strategies: passively targeting tumor tissue by enhanced permeability and retention effect, actively targeting tumor cells by cluster determinant 44 (CD44) receptor, and then entering cells through receptor-mediated endocytosis. In this review, the synthesis of HA nanoparticles is described in detail from several aspects and applications are also discussed for improving the delivery of hydrophobic drugs, nucleic acids and photosensitizers into the tumor cells. In addition, the modification of HA for improving the targeting and drug releasing characteristics are also discussed.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hierarchical targeting strategies; Modification of HA; Receptor-mediated endocytosis; Synthesis of HA nanoparticles

Mesh:

Substances:

Year:  2018        PMID: 30658811     DOI: 10.1016/j.carbpol.2018.12.074

Source DB:  PubMed          Journal:  Carbohydr Polym        ISSN: 0144-8617            Impact factor:   9.381


  9 in total

1.  Hyaluronic acid derivative-modified nano-structured lipid carrier for cancer targeting and therapy.

Authors:  Xiao Liu; Hai Liu; Su-Lan Wang; Jing-Wen Liu
Journal:  J Zhejiang Univ Sci B       Date:  2020-07       Impact factor: 3.066

Review 2.  CD44-Targeted Nanocarrier for Cancer Therapy.

Authors:  Prashant Kesharwani; Rahul Chadar; Afsana Sheikh; Waleed Y Rizg; Awaji Y Safhi
Journal:  Front Pharmacol       Date:  2022-03-31       Impact factor: 5.810

3.  Novel multifunctional triple folic acid, biotin and CD44 targeting pH-sensitive nano-actiniaes for breast cancer combinational therapy.

Authors:  Mengna Liu; Bingjie Wang; Chunjing Guo; Xiaoya Hou; Ziting Cheng; Daquan Chen
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

4.  Ultrasound Mediated Destruction of LMW-HA-Loaded and Folate-Conjugated Nanobubble for TAM Targeting and Reeducation.

Authors:  Xiao Sun; Lu Guo; Mengmeng Shang; Dandan Shi; Ping Liang; Xuanxuan Jing; Dong Meng; Xinxin Liu; Xiaoying Zhou; Yading Zhao; Jie Li
Journal:  Int J Nanomedicine       Date:  2020-03-23

5.  Bacterial Genotoxin-Coated Nanoparticles for Radiotherapy Sensitization in Prostate Cancer.

Authors:  Yu-An Chen; Yi-Ru Lai; Hui-Yu Wu; Yen-Ju Lo; Yu-Fang Chang; Chiu-Lien Hung; Chun-Jung Lin; U-Ging Lo; Ho Lin; Jer-Tsong Hsieh; Cheng-Hsun Chiu; Yu-Hsin Lin; Chih-Ho Lai
Journal:  Biomedicines       Date:  2021-02-04

Review 6.  Tunneling Nanotubes: A New Target for Nanomedicine?

Authors:  Ilaria Ottonelli; Riccardo Caraffi; Giovanni Tosi; Maria Angela Vandelli; Jason Thomas Duskey; Barbara Ruozi
Journal:  Int J Mol Sci       Date:  2022-02-17       Impact factor: 5.923

Review 7.  CD44 In Sarcomas: A Comprehensive Review and Future Perspectives.

Authors:  Enrique Fernández-Tabanera; Raquel M Melero-Fernández de Mera; Javier Alonso
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

8.  Enzyme-triggered- and tumor-targeted delivery with tunable, methacrylated poly(ethylene glycols) and hyaluronic acid hybrid nanogels.

Authors:  Wioletta Liwinska; Ewelina Waleka-Bagiel; Zbigniew Stojek; Marcin Karbarz; Ewelina Zabost
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

9.  Lentinan-functionalized Selenium Nanoparticles target Tumor Cell Mitochondria via TLR4/TRAF3/MFN1 pathway.

Authors:  Hui-Juan Liu; Yuan Qin; Zi-Han Zhao; Yang Zhang; Jia-Huan Yang; Deng-Hui Zhai; Fang Cui; Ce Luo; Man-Xi Lu; Piao-Piao Liu; Heng-Wei Xu; Kun Li; Bo Sun; Shuang Chen; Hong-Gang Zhou; Cheng Yang; Tao Sun
Journal:  Theranostics       Date:  2020-07-11       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.